<DOC>
	<DOCNO>NCT01417052</DOCNO>
	<brief_summary>The primary objective study determine safety LX3305 dose escalation compare placebo 12 week subject active rheumatoid arthritis ( RA ) .</brief_summary>
	<brief_title>A Study Determine Safety Efficacy LX3305 Subjects With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult subject , age 18 75 year Active rheumatoid arthritis ( RA ) , class I III ( defined American College Rheumatology ) , diagnose least 3 month prior Screening Minimum 4 swollen joint ( Screening Day 1 ) , minimum 4 tender joint ( Screening Day 1 ) , serum Creactive protein ( CRP ) level &gt; 1.2x upper limit normal and/or elevate erythrocyte sedimentation rate ( ESR ) If receive methotrexate ( 7.5 mg 25 mg/week ) , subject must treat least 6 week prior Screening currently receive stable dose methotrexate ( MTX ) stable route administration , plan change MTX dose study Ability give write informed consent Women pregnant nursing RA diagnosis prior 16 year age ( juvenile RA ) Intraarticular and/or parenteral corticosteroid within 4 week study Day 1 Receipt live vaccine within 4 week prior Day 1 Major surgical procedure within 8 week prior Day 1 Blood donation within 4 week prior Day 1 Any systemic inflammatory condition History bleed diathesis History medically significant opportunistic infection History drug alcohol abuse within 3 year prior Day 1 History cancer within 5 year prior Day 1 Presence hepatic biliary disease History tuberculosis History human immunodeficiency virus ( HIV ) Any clinically significant laboratory test result , opinion investigator Use investigational agent participation investigative trial within 30 day Day 1 Concurrent use biologic agent treatment RA concomitant disease modify antirheumatoid drug ( MTX , hydroxychloroquine , leflunomide , sulfasalazine stable dose 8 week )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>